- Home
- MFM vs ADAP Comparison
MFM vs ADAP Comparison
Compare MFM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- ADAP
- Stock Information
- Founded
- MFM 1986
- ADAP 2008
- Country
- MFM United States
- ADAP United Kingdom
- Employees
- MFM N/A
- ADAP N/A
- Industry
- MFM Finance Companies
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- MFM Finance
- ADAP Health Care
- Exchange
- MFM Nasdaq
- ADAP Nasdaq
- Market Cap
- MFM 235.2M
- ADAP 212.3M
- IPO Year
- MFM N/A
- ADAP 2015
- Fundamental
- Price
- MFM $5.59
- ADAP $0.59
- Analyst Decision
- MFM
- ADAP Strong Buy
- Analyst Count
- MFM 0
- ADAP 4
- Target Price
- MFM N/A
- ADAP $3.16
- AVG Volume (30 Days)
- MFM 108.1K
- ADAP 2.0M
- Earning Date
- MFM 01-01-0001
- ADAP 11-13-2024
- Dividend Yield
- MFM 4.08%
- ADAP N/A
- EPS Growth
- MFM N/A
- ADAP N/A
- EPS
- MFM 0.03
- ADAP N/A
- Revenue
- MFM N/A
- ADAP $175,041,000.00
- Revenue This Year
- MFM N/A
- ADAP $180.15
- Revenue Next Year
- MFM N/A
- ADAP N/A
- P/E Ratio
- MFM $176.67
- ADAP N/A
- Revenue Growth
- MFM N/A
- ADAP 146.27
- 52 Week Low
- MFM $4.37
- ADAP $0.42
- 52 Week High
- MFM $5.48
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- MFM 49.87
- ADAP 26.22
- Support Level
- MFM $5.53
- ADAP $0.75
- Resistance Level
- MFM $5.60
- ADAP $0.83
- Average True Range (ATR)
- MFM 0.05
- ADAP 0.07
- MACD
- MFM 0.01
- ADAP -0.01
- Stochastic Oscillator
- MFM 72.22
- ADAP 2.36
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.